• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    1/23/24 12:31:00 PM ET
    $ACON
    $BCEL
    $ENSC
    $EVOK
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Ensysce Biosciences (NASDAQ:ENSC) shares moved upwards by 46.5% to $1.67 during Tuesday's regular session. The market value of their outstanding shares is at $5.2 million.
    • Turnstone Biologics (NASDAQ:TSBX) stock rose 33.55% to $3.0. The market value of their outstanding shares is at $69.3 million.
    • Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 33.08% to $3.54. The company's market cap stands at $57.9 million.
    • Outlook Therapeutics (NASDAQ:OTLK) stock increased by 24.49% to $0.42. The company's market cap stands at $110.1 million.
    • Jin Medical International (NASDAQ:ZJYL) stock rose 22.42% to $131.0. The company's market cap stands at $1.0 billion.
    • Catheter Precision (AMEX:VTAK) shares rose 21.89% to $0.59. The company's market cap stands at $4.1 million.

    Losers

    • Nutex Health (NASDAQ:NUTX) shares declined by 25.6% to $0.14 during Tuesday's regular session. The company's market cap stands at $93.6 million.
    • Atreca (NASDAQ:BCEL) stock fell 16.51% to $0.22. The company's market cap stands at $8.6 million.
    • Gyre Therapeutics (NASDAQ:GYRE) stock declined by 16.02% to $16.21. The company's market cap stands at $1.2 billion.
    • Aclarion (NASDAQ:ACON) shares declined by 14.18% to $2.24. The market value of their outstanding shares is at $1.8 million.
    • Panbela Therapeutics (NASDAQ:PBLA) shares fell 12.68% to $3.79. The company's market cap stands at $1.8 million.
    • Evoke Pharma (NASDAQ:EVOK) shares declined by 12.6% to $0.62. The market value of their outstanding shares is at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $BCEL
    $ENSC
    $EVOK

    CompanyDatePrice TargetRatingAnalyst
    Sensus Healthcare Inc.
    $SRTS
    3/6/2026$7.50Buy
    Alliance Global Partners
    Gyre Therapeutics Inc.
    $GYRE
    10/10/2025$16.00Buy
    Jefferies
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Gyre Therapeutics Inc.
    $GYRE
    8/26/2025$18.00Buy
    H.C. Wainwright
    Gyre Therapeutics Inc.
    $GYRE
    3/11/2025Outperform
    Noble Capital Markets
    Turnstone Biologics Corp.
    $TSBX
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    Sensus Healthcare Inc.
    $SRTS
    1/31/2025$18.00Buy
    Lake Street
    More analyst ratings

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth

    FORT MILL, S.C., March 11, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced transformational balance sheet improvements through new institutional capital commitments supporting the Company's next phase of growth. Fully Funded Growth StrategyFly Flyte, Inc. ("Flyte"), a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent company, Catheter Precision. VTAK has recently completed multiple strategic financings designed to support the Company's transformation and the expansion of the Flyte aviation platform. The financing also provides capital to fund the Company's medical d

    3/11/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

    Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL CommercializationFORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. ("Flyte") from Creatd, Inc. (OTCQB:CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the ow

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    3/10/26 4:30:54 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Nutex Health Inc.

    S-8 - Nutex Health Inc. (0001479681) (Filer)

    3/10/26 11:35:55 AM ET
    $NUTX
    Real Estate

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/9/26 5:06:37 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Financial Officer Bates Jon Christian bought $102,532 worth of shares (750 units at $136.71), increasing direct ownership by 15% to 5,638 units (SEC Form 4)

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    11/28/25 2:11:24 PM ET
    $NUTX
    Real Estate

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Sensus Healthcare with a new price target

    Alliance Global Partners initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.50

    3/6/26 8:35:41 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Jefferies initiated coverage on Gyre Therapeutics with a new price target

    Jefferies initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $16.00

    10/10/25 8:38:16 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outlook Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral

    8/29/25 8:20:01 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIMOTI

    Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

    1/15/21 5:10:35 AM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    2/18/26 4:16:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Biscotti Larry Joseph

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/18/26 3:48:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

    1/7/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Financials

    Live finance-specific insights

    View All

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    Nutex Health Schedules 2025 Fourth Quarter and Year-End Financial Results and Earnings Conference Call

    HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, March 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and

    2/25/26 5:29:00 PM ET
    $NUTX
    Real Estate

    $ACON
    $BCEL
    $ENSC
    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care